CollPlant Biotechnologies (CLGN) Common Equity (2017 - 2025)
CollPlant Biotechnologies' (CLGN) quarterly Common Equity came in at $6.1 million in Q4 2025, down 54.84% YoY from $13.5 million in Q4 2024, and down 34.65% on a QoQ basis from $9.3 million in Q3 2025.
CollPlant Biotechnologies (CLGN) Common Equity (2017 - 2025) Analysis & Trends
CollPlant Biotechnologies (CLGN) has 9 years of Common Equity data on file, last reported at $6.1 million in Q4 2025.
- Quarterly Common Equity fell 54.84% year-over-year to $6.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $6.1 million (down 54.84% YoY) and the FY2025 annual result came in at $6.1 million, down 54.84% from the prior year.
- Common Equity eased to $6.1 million in Q4 2025, from $9.3 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $50.6 million in Q1 2021 to a low of $6.1 million in Q4 2025.
- A 5-year average of $30.2 million and a median of $32.3 million in 2022 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2021 — Common Equity soared 907.84% — and 2025, when it sank 54.84%.
- Tracing CLGN's Common Equity over 5 years: stood at $45.1 million in 2021, then declined by 28.46% to $32.3 million in 2022, then slipped by 12.21% to $28.3 million in 2023, then sank by 52.49% to $13.5 million in 2024, then sank by 54.84% to $6.1 million in 2025.
- The last three Common Equity figures came in at $6.1 million (Q4 2025), $9.3 million (Q3 2025), and $12.5 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | CollPlant Biotechnologies | 4.13 Mn | 4.13 Mn | -243,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.08 Mn |
| Sep 30, 2025 | 9.31 Mn |
| Jun 30, 2025 | 12.51 Mn |
| Dec 31, 2024 | 13.47 Mn |
| Sep 30, 2024 | 16.92 Mn |
| Jun 30, 2024 | 20.73 Mn |
| Mar 31, 2024 | 24.45 Mn |
| Dec 31, 2023 | 28.34 Mn |
| Sep 30, 2023 | 32.40 Mn |
| Jun 30, 2023 | 36.04 Mn |
| Mar 31, 2023 | 29.89 Mn |
| Dec 31, 2022 | 32.28 Mn |
| Sep 30, 2022 | 35.81 Mn |
| Jun 30, 2022 | 39.51 Mn |
| Mar 31, 2022 | 43.20 Mn |
| Dec 31, 2021 | 45.12 Mn |
| Sep 30, 2021 | 48.48 Mn |
| Jun 30, 2021 | 49.44 Mn |
| Mar 31, 2021 | 50.65 Mn |
| Dec 31, 2020 | 4.48 Mn |